logo-loader
viewPressure BioSciences, Inc.

Pressure BioSciences says more than 20 scientific papers cited benefits of PCT platform

Pressure BioSciences Inc's (OTCQB: PBIO) Global Director of Sales & Marketing Roxana McCloskey tells Proactive Investors that more than 20 journal articles describing the advantages of its pressure cycling technology (PCT) platform were published in 2018.

McCloskey says it's exciting to see these publications, including the Journal of Proteomics, issuing research on PCT and expanding the credibility of the PCT platform.

Quick facts: Pressure BioSciences, Inc.

Price: 2.25 USD

OTCMKTS:PBIO
Market: OTCQB
Market Cap: $5.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

on 10/04/2019

2 min read